BOUT:NYE-Innovator ETFs Trust - Innovator IBD Breakout Opportunities ETF (USD)

ETF | Mid-Cap Growth |

Last Closing

USD 37.8

Change

+0.73 (+1.97)%

Market Cap

USD 0.01B

Volume

1.30K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-17 )

Largest Industry Peers for Mid-Cap Growth

Symbol Name Price(Change) Market Cap
IWP iShares Russell Mid-Cap Growth..

-2.34 (-1.94%)

USD 15.82B
VOT Vanguard Mid-Cap Growth Index ..

-3.08 (-1.24%)

USD 14.48B
IJK iShares S&P Mid-Cap 400 Growth..

-1.31 (-1.54%)

USD 8.67B
XMMO Invesco S&P MidCap Momentum ET..

-1.43 (-1.24%)

USD 3.54B
IVOG Vanguard S&P Mid-Cap 400 Growt..

-1.32 (-1.25%)

USD 1.01B
ETHO Amplify ETF Trust

-0.45 (-0.80%)

USD 0.18B
CWS AdvisorShares Focused Equity E..

-0.25 (-0.38%)

USD 0.17B
BFOR Barron's 400 ETF

-0.59 (-0.85%)

USD 0.14B
IPO Renaissance IPO ETF

-0.95 (-2.38%)

USD 0.13B
PEXL Pacer US Export Leaders ETF

-0.42 (-0.88%)

USD 0.05B

ETFs Containing BOUT

N/A

Market Performance

  Market Performance vs. Industry/Classification (Mid-Cap Growth) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.25% 69% C- 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.25% 69% C- 32% F
Trailing 12 Months  
Capital Gain 7.63% 81% B- 65% D
Dividend Return 0.02% 8% B- N/A F
Total Return 7.65% 81% B- 56% F
Trailing 5 Years  
Capital Gain 137.44% 78% C+ 71% C-
Dividend Return 5.28% 33% F 8% B-
Total Return 142.72% 78% C+ 65% D
Average Annual (5 Year Horizon)  
Capital Gain 12.87% 72% C 71% C-
Dividend Return 13.47% 72% C 67% D+
Total Return 0.60% 50% F 15% F
Risk Return Profile  
Volatility (Standard Deviation) 25.11% 61% D- 43% F
Risk Adjusted Return 53.65% 72% C 67% D+
Market Capitalization 0.01B 8% B- 8% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.